文献速递食管胃疾病与幽门螺杆菌

改良双联疗法与含铋四联疗法作为幽门螺杆菌一线治疗的根除疗效比较

Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

本研究为开放标签随机对照试验,纳入232例幽门螺杆菌感染初治患者,比较14天改良双联疗法与含铋四联疗法的根除率、不良反应、依从性和费用。改良双联疗法根除率与含铋四联疗法相似,总体副作用显著更少(P < 0.001),药物费用更低。

要点

  • 改良双联疗法根除率与含铋四联疗法相似。
  • 改良双联疗法总体副作用显著少于含铋四联疗法(P < 0.001)。
  • 改良双联疗法药物费用低于含铋四联疗法。

核心结论

  • 高剂量、高频给药的改良双联疗法与含铋四联疗法同样有效,且更安全、费用更低。

研究设计与样本

  • 开放标签、随机对照临床试验,共纳入232例幽门螺杆菌感染初治患者,随机分为14天改良双联疗法组和含铋四联疗法组。

主要发现

  • 改良双联疗法组意向性分析、符合方案分析和改良意向性分析根除率分别为87.9%、91.1%和91.1%。
  • 含铋四联疗法组意向性分析、符合方案分析和改良意向性分析根除率分别为89.7%、91.2%和90.4%。
  • 改良双联疗法减轻了CYP2C19、IL-1B-511和幽门螺杆菌VacA基因型变异的影响。
  • 两组依从率无显著差异。
  • 改良双联疗法组总体副作用显著少于含铋四联疗法组(P < 0.001)。

关键数值与推荐

  • 改良双联疗法组根除率:意向性分析87.9%,符合方案分析91.1%,改良意向性分析91.1%。
  • 含铋四联疗法组根除率:意向性分析89.7%,符合方案分析91.2%,改良意向性分析90.4%。
  • 改良双联疗法组总体副作用显著少于含铋四联疗法组(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study assessed the effectiveness, adverse events, patient adherence, and costs of modified dual therapy compared with bismuth-containing quadruple therapy for treating Helicobacter pylori infection in Chinese patients. We also sought to determine whether modified dual therapy could be used as an alternative first-line treatment for H. pylori infection. METHODS: A total of 232 H. pylori-infected, treatment-naive patients were enrolled in this open-label, randomized controlled clinical trial. Patients were randomly allocated into 2 groups: the 14-day modified dual therapy group and the bismuth-containing quadruple therapy group. Eradication rates, drug-related adverse events, patient compliance, and drug costs were compared between the 2 groups. RESULTS: The modified dual therapy group achieved eradication rates of 87.9%, 91.1%, and 91.1% as determined by the intention-to-treat, per-protocol, and modified intention-to-treat analyses, respectively. The eradication rates were similar compared with the bismuth-containing quadruple therapy group: 89.7%, 91.2%, and 90.4%. In addition, modified dual therapy ameliorated variations in the CYP2C19, IL-1B-511, and H. pylori VacA genotypes. There were no significant differences in the compliance rates between the 2 groups. The modified dual therapy group exhibited significantly less overall side effects compared with the bismuth-containing quadruple therapy group (P < 0.001). Furthermore, the cost of medications in the modified dual therapy was lower compared with that in the bismuth-containing quadruple therapy. CONCLUSIONS: Modified dual therapy at high dose and administration frequency is equally effective and safer and less costly compared with bismuth-containing quadruple therapy.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Yang J, Zhang Y, Fan L, et al. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori. Am J Gastroenterol. 2019. PMID: 30807294. doi:10.14309/ajg.0000000000000132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。